Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.
The biopharmaceutical company reported Q2 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. Kiniksa's Q2 sales reached $156.797 million, exceeding the expected $145.218 million. The company's net income for the quarter stood at $17.832 million, with a pretax profit of $22.877 million, showcasing robust financial performance.
In a significant move, Kiniksa raised its 2025 net product revenue guidance for ARCALYST, its flagship product. The company now expects ARCALYST to generate between $625 million and $640 million in revenue for the year, up from the previous guidance of $590 million to $605 million. This upward revision signals strong confidence in the drug's market performance and potential growth. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, further bolstering its pipeline prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.